Business Context and Reporting Period
This Form 8-K reports on the 2021 Annual Meeting of Stockholders held by Salarius Pharmaceuticals, Inc. on June 16, 2021. The filing details the results of four proposals submitted to security holders. Note: The input metadata references "Decoy Therapeutics Inc.," but the filing text explicitly identifies the registrant as Salarius Pharmaceuticals, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
The following proposals were voted upon at the Annual Meeting:
- Proposal 1 (Election of Directors): Two Class III directors were elected to serve until the 2024 annual meeting.
- Tess Burleson: 11,267,742 votes For; 759,606 votes Withheld.
- Paul Lammers: 11,268,242 votes For; 759,106 votes Withheld.
- Proposal 2 (Say-on-Pay): Non-binding advisory vote on executive compensation.
- 11,003,098 votes For; 830,994 votes Against; 193,256 Abstentions.
- Proposal 3 (Auditor Ratification): Ratification of Ernst & Young LLP as independent auditors for fiscal year 2021.
- 23,584,404 votes For; 763,263 votes Against; 138,632 Abstentions.
- Proposal 4 (Say-on-Pay Frequency): Non-binding advisory vote on the frequency of executive compensation votes.
- One Year: 11,257,837 votes (Selected).
- Two Years: 162,599 votes.
- Three Years: 465,581 votes.
- Abstentions: 141,331 votes.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of stockholder voting results.
Investor Verification Checklist
- Verify the correct registrant name is Salarius Pharmaceuticals, Inc. (SLRX), not Decoy Therapeutics.
- Confirm the election of Tess Burleson and Paul Lammers to the Board of Directors.
- Note that stockholders voted to hold the advisory vote on executive compensation annually (One Year).
- Review the Proxy Statement for the Annual Meeting for detailed context on the nominees and compensation policies.